Antimicrobial resistance development and therapy, Fungal pathogenesis, Candida biofilm pathogenesis and resistance, preclinical anti-infective drug development
Breast cancer, tumor/stromal interactions, cancer stem cells, mammary stem cells, Human-in-Mouse Model, inflammation and tumor microenvironment, adipose stem cells
Myeloma research and phase I experimental therapeutics
Acquired immunologic tolerance; graft acceptance through the study of transplant recipients who have survived even though they have stopped taking immunosuppressive drugs; Th17 and Treg development
Using mouse models of allogeneic blood and marrow transplantation (alloBMT) to optimize therapies that prevent graft-versus-host-disease (GVHD) and maximize graft-versus-tumor (GVT) effects
Evolution of host-microbe interactions, including both pathogenic and beneficial microbes. We are particularly interested in: i) the evolution of virulence, ii) determining the factors that shape host-microbe specificity, iii) exploring factors limiting and/or facilitating broad host jumps, iv) and host-microbe coevolutionary dynamics. Our main model system is the fungus-growing ant–microbe symbiosis.
Host-pathogen interactions; the role of macrophages in immunity to intracellular pathogens; innate immune responses like cytokine production & microbial killing amplified by extracellular nucleotide receptor known as P2X7 (significant functional diversity for this receptor exists between cell types & human subjects); role of P2X7 as candidate gene modulating the human innate immune responses of macrophages & airway epithelial cells to Chlamydia pneumoniae, contribution of responses of asthma
The cellular and molecular mechanisms of fibrogenesis in native and transplant kidney disease
Type 1 diabetes (T1D) results from the destruction of the insulin-secreting b-cells by an immune mediated process. The increasing incidence of type 1 diabetes around the word, especially among children, has been of great concern.